{"id":120839,"date":"2025-05-21T21:39:12","date_gmt":"2025-05-21T21:39:12","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/120839\/"},"modified":"2025-05-21T21:39:12","modified_gmt":"2025-05-21T21:39:12","slug":"ai-guided-gene-vectors-precisely-target-brain-and-spinal-cells","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/120839\/","title":{"rendered":"AI-Guided Gene Vectors Precisely Target Brain and Spinal Cells"},"content":{"rendered":"<p><strong>Summary: <\/strong>Scientists have engineered dozens of adeno-associated virus (AAV) systems that ferry genes to specific neuron and glial subtypes in the brain and spinal cord with unprecedented accuracy. Powered by AI-selected DNA \u201clight switches,\u201d the vectors can switch on therapeutic or research genes only in targeted cells, eliminating the need for transgenic animals and enabling fine-grained circuit mapping, activation, or silencing.<\/p>\n<p>Validated across multiple species and human surgical tissue, the toolkit reaches elusive cells implicated in disorders like ALS, epilepsy, and Parkinson\u2019s disease. By focusing treatment on malfunctioning cells alone, these tools lay a foundation for next-generation brain gene therapies that address root causes rather than symptoms.<\/p>\n<p><strong>Key Facts:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Cell-Specific Vectors:<\/strong> Dozens of AAVs precisely target excitatory, inhibitory, vascular, and spinal motor neurons.<\/li>\n<li><strong>AI-Found Enhancers:<\/strong> Machine-learning algorithms identify DNA switches that direct cell-type-specific gene expression.<\/li>\n<li><strong>Ready for Researchers:<\/strong> All vectors, SOPs, and guides are freely available via Addgene, accelerating global brain research.<\/li>\n<\/ul>\n<p><strong>Source: <\/strong>NIH<\/p>\n<p><strong>Research teams funded by the National Institutes of Health (NIH) have created a versatile set of gene delivery systems that can reach different neural cell types in the human brain and spinal cord with exceptional accuracy. <\/strong><\/p>\n<p>These delivery systems are a significant step toward future precise gene therapy to the brain that could safely control errant brain activity with high precision. In contrast, current therapies for brain disorders mostly treat only symptoms.<\/p>\n<p>The new delivery systems carry genetic material into the brain and spinal cord for targeted use by specific cell types. This platform has the potential to transform how scientists can study neural circuits.<\/p>\n<p>  <img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"799\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/brain-spinal-cell-genetic-delivery-neuroscience.jpg\" alt=\"This shows a brain.\"  \/> The delivery systems have been tested, or validated, in intact living systems, which is an important step for introducing new tools for widespread use. Credit: Neuroscience News<\/p>\n<p>It provides researchers with gene delivery systems for various species used in research, without the need for genetically modified, or transgenic, animals. Examples include illuminating fine structures of brain cells with fluorescent proteins and activating or silencing circuits that control behavior and cognition.<\/p>\n<p>\u201cImagine this new platform as a delivery truck dropping off specialized genetic packages in specific cell neighborhoods in the brain and spinal cord,\u201d said John Ngai, Director of the NIH\u2019s\u00a0Brain Research Through Advancing Innovative Neurotechnologies\u00ae\u00a0Initiative, or\u00a0The\u00a0BRAIN\u00a0Initiative\u00ae.<\/p>\n<p>\u201cWith these delivery systems, we can now access and manipulate specific cells in the brain and spinal cord \u2013 access that was not possible before at this scale.\u201d<\/p>\n<p>The new delivery tools, which use a small, stripped-down adeno-associated virus (AAV) to deliver DNA to target cells, can be broadly applied across many species and experimental systems, including small tissue samples removed during human brain surgeries.<\/p>\n<p>The delivery systems have been tested, or validated, in intact living systems, which is an important step for introducing new tools for widespread use. The newly published toolkit includes:<\/p>\n<ul class=\"wp-block-list\">\n<li>Dozens of delivery systems that selectively target key brain cell types, including excitatory neurons, inhibitory interneurons, striatal and cortical subtypes, brain blood vessel cells, and hard-to-reach neurons in the spinal cord that control body movement and are damaged in several neurological diseases, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy<\/li>\n<li>Computer programs powered by artificial intelligence (AI) that can identify genetic \u201clight switches,\u201d known as enhancers, that turn genes on in specific brain cell types, using data from many different species \u2013 cutting considerable time and effort for scientists looking for these genetic switches.<\/li>\n<\/ul>\n<p>Overall, this collection of research tools will significantly accelerate understanding of the human brain.<\/p>\n<p>Importantly, the toolkit enables access to specific brain cell types in the prefrontal cortex, an area that\u2019s critical for decision-making and uniquely human traits.<\/p>\n<p>With other tools in the collection, scientists can better study individual cells and communication pathways known to be affected in several neurological diseases.<\/p>\n<p>These include seizure disorders, ALS, Parkinson\u2019s disease, Alzheimer\u2019s disease, and Huntington\u2019s disease \u2013 as well as various neuropsychiatric conditions.<\/p>\n<p>AAV-based treatments are already approved for some conditions, such as spinal muscular atrophy for which a 2016 approval of a gene therapy known as Zolgensma transformed the lives of infants and young children who once faced severe disability or early death.<\/p>\n<p>The new collection of gene delivery resources lays the groundwork for more precise treatments that target only affected cells in the brain, spinal cord, or brain blood vessels.<\/p>\n<p>The toolkit is available at distribution centers including\u00a0Addgene, a global supplier of genetic research tools.<\/p>\n<p>This collection of publications offers researchers standard operating procedures and user guides for these tools.<\/p>\n<p>The work is supported by the NIH\u2019s\u00a0Brain Research Through Advancing Innovative Neurotechnologies\u00ae\u00a0Initiative, or\u00a0The\u00a0BRAIN\u00a0Initiative\u00ae.<\/p>\n<p>Funding issued less than four years ago launched a large-scale, team-run project to design new molecular tools that can be useful to many research laboratories.<\/p>\n<p>The\u00a0Armamentarium\u00a0for Precision Brain Cell Access\u00a0aims to develop precise and reproducible access to cells and circuits in experimental research models of the brain and spinal cord.\u00a0<\/p>\n<p>The large-scale project brings together experts in the field of molecular biology, neuroscience, and artificial intelligence (AI).<\/p>\n<p><strong>Grants:<\/strong>\u00a0UF1MH130701, UH3MH120096, U24MH133236, UF1MH128339, UM1MH130981, R01MH123620, U19MH114830, P510D010425, U420D011123, S10MH126994, UH3MH120094, UF1MH130881, F30DA053020, R01FD007478, U01AG076791, R35GM127102, RF1MH114126, UH3MH120095, RF1MH121274, R01MH113005, UH3MH120095.<\/p>\n<p>About this genetic engineering research news<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Author: <\/strong><a href=\"http:\/\/neurosciencenews.com\/cdn-cgi\/l\/email-protection#216f68697153445252614f48490f464e57\" target=\"_blank\" rel=\"noreferrer noopener\">NIH Office of Communications<\/a><br \/><strong>Source: <\/strong><a href=\"https:\/\/nih.gov\" target=\"_blank\" rel=\"noreferrer noopener\">NIH<\/a><br \/><strong>Contact: <\/strong>NIH Office of Communications \u2013 NIH<br \/><strong>Image: <\/strong>The image is credited to Neuroscience News<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Original Research: <\/strong>Open access.<br \/>\u201c<a href=\"https:\/\/doi.org\/10.1016\/j.neuron.2025.05.002\" target=\"_blank\" rel=\"noreferrer noopener\">An enhancer-AAV toolbox to target and manipulate distinct interneuron subtypes<\/a>\u201d by Elisabetta\u00a0Furlanis et al. Cell<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p><strong>An enhancer-AAV toolbox to target and manipulate distinct interneuron subtypes<\/strong><\/p>\n<p>In recent years, we and others have identified a number of enhancers that, when incorporated into rAAV vectors, can restrict the transgene expression to particular neuronal populations.<\/p>\n<p>Yet, viral tools to access and manipulate specific neuronal subtypes are still limited.<\/p>\n<p>Here, we performed systematic analysis of single-cell genomic data to identify enhancer candidates for each of the telencephalic interneuron subtypes.<\/p>\n<p>We established a set of enhancer-AAV tools that are highly specific for distinct cortical interneuron populations and striatal cholinergic interneurons.<\/p>\n<p>These enhancers, when used in the context of different effectors, can target (fluorescent proteins), observe activity (GCaMP), and manipulate (opto-genetics) specific neuronal subtypes. We also validated our enhancer-AAV tools across species.<\/p>\n<p>Thus, we provide the field with a powerful set of tools to study neural circuits and functions and to develop precise and targeted therapy.<\/p>\n","protected":false},"excerpt":{"rendered":"Summary: Scientists have engineered dozens of adeno-associated virus (AAV) systems that ferry genes to specific neuron and glial&hellip;\n","protected":false},"author":2,"featured_media":120840,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[323,1942,215,3725,3899,36916,267,3690,219,233,220,34930,70,16,15],"class_list":{"0":"post-120839","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-ai","9":"tag-artificial-intelligence","10":"tag-brain-research","11":"tag-deep-learning","12":"tag-genetic","13":"tag-genetic-engineering","14":"tag-genetics","15":"tag-machine-learning","16":"tag-neurobiology","17":"tag-neurology","18":"tag-neuroscience","19":"tag-nih","20":"tag-science","21":"tag-uk","22":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114547993908126726","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/120839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=120839"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/120839\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/120840"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=120839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=120839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=120839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}